TNXP

 Tonix Pharmaceuticals has a diverse pipeline of drugs in various stages of development. Here are some of the key candidates:

TNX-102 SL: This is their lead candidate for fibromyalgia, with two positive Phase 3 studies completed. They plan to file a New Drug Application (NDA) in the second half of 2024. It’s also being developed for acute stress disorder and fibromyalgia-type Long COVID1.

TNX-1300: Currently in mid-Phase 2, this drug is for treating cocaine intoxication and has received Breakthrough Therapy Designation1.

TNX-1500: This is in Phase 1 for preventing organ transplant rejection and treating autoimmune disorders1.

TNX-1700: In preclinical development for gastric and colorectal cancer1.

TNX-801: A vaccine candidate for smallpox and monkeypox, currently in preclinical stages1.

TNX-1800: A COVID-19 vaccine candidate, also in preclinical development1.

TNX-2900: This drug is in Phase 2 for Prader-Willi Syndrome and has received FDA Orphan Drug and Rare Pediatric Disease Designation1.

Tonix is also working on other programs targeting central nervous system disorders, immunology conditions, infectious diseases, and rare diseases1.

EOSE

 https://finance.yahoo.com/quote/EOSE/news/

TNXP up 11.76%

 TNXP up today

11share

0.6073 AVG

0.37 market 

(39.07% down) 

avg volume 24.6M 

today 4.58M

market cap 7.49M 

(1) Tonix initiates Phase II trial for emergency cocaine intoxication treatment ( August 20 prices up to 0.85$  107M volume) 

Tonix Pharmaceuticals has initiated a Phase II clinical trial for TNX-1300, a treatment for acute cocaine intoxication. This trial is a single-blind, placebo-controlled, proof-of-concept study being conducted in emergency departments across six academic medical centers in the U.S. The study aims to enroll 60 patients and will compare the safety and efficacy of TNX-1300 to a placebo12.

Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, immunology, and infectious diseases. 

The company has received a consensus rating of “Buy” from analysts1. 

They have several promising candidates in their pipeline, including treatments for fibromyalgia and cocaine intoxication23.

However, like many biopharmaceutical companies, Tonix faces challenges such as regulatory hurdles and the need for successful clinical trials. Their stock has experienced significant volatility, which is common in this sector1.

Overall, Tonix Pharmaceuticals shows potential, but it’s important to consider the inherent risks in investing in clinical-stage biotech companies.

If you have any specific questions or need more details, feel free to ask!